10 results on '"Jia, Huixun"'
Search Results
2. Association of exposure to ultraviolet radiation and warm-season ozone air pollution with incident age-related macular degeneration: A nationwide cohort study in China
- Author
-
Qu, Yanlin, Jiang, Yichen, Zhang, Guanran, Luo, Huihuan, Hu, Weiting, Wu, Zhenyu, Meng, Xia, Chen, Renjie, Jia, Huixun, and Sun, Xiaodong
- Published
- 2024
- Full Text
- View/download PDF
3. Association of long-term ozone air pollution and age-related macular degeneration in older Chinese population
- Author
-
Jia, Huixun, Guo, Yi, Luo, Huihuan, Meng, Xia, Zhang, Lina, Yu, Kexin, Zheng, Xueying, Sun, Yiqing, Hu, Weiting, Wu, Zhenyu, Chen, Renjie, and Sun, Xiaodong
- Published
- 2024
- Full Text
- View/download PDF
4. Predicting the pathological response to neoadjuvant chemoradiation using untargeted metabolomics in locally advanced rectal cancer
- Author
-
Jia, Huixun, Shen, Xiaotao, Guan, Yun, Xu, Meimei, Tu, Jia, Mo, Miao, Xie, Li, Yuan, Jing, Zhang, Zhen, Cai, Sanjun, Zhu, Ji, and Zhu, ZhengJiang
- Published
- 2018
- Full Text
- View/download PDF
5. CircRNA Uxs1/miR-335-5p/PGF axis regulates choroidal neovascularization via the mTOR/p70 S6k pathway.
- Author
-
Wu, Jiali, Chen, Jieqiong, Hu, Jing, Yao, Mudi, Zhang, Min, Wan, Xiaoling, Jia, Huixun, Wang, Fenghua, and Sun, Xiaodong
- Abstract
Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness in the elderly population. Neovascular AMD is the late stage, characterized by choroidal neovascularization (CNV). Non-coding RNAs have been implicated in CNV; however, the role of circular RNAs (circRNAs) has not yet been elucidated. Herein, we comprehensively investigated circRNA profiles in laser-induced CNV mouse models and patient specimens. A novel circRNA, circRNA Uxs1, was identified, and its function in CNV regulation was investigated in the present study. CircRNA Uxs1 was consistently upregulated in CNV patient specimens and CNV mouse models. Knockdown of circRNA Uxs1 interrupted the tube formation, migration, and proliferation of endothelial cells in vitro. Silencing circRNA Uxs1 in vivo alleviated neovascularization formation, as shown by the decreased size of laser spots. Mechanistically, circRNA Uxs1 functioned by binding to miR-335-5p, which further upregulated the expression of placental growth factor (PGF) gene and activated the mammalian target of rapamycin/p70 S6 Kinase (mTOR/p70 S6k) pathway. By subretinal injections of adeno-associated virus (AAV), we demonstrated the anti-angiogenic function of circRNA Uxs1 knockdown in vivo. In conclusion, circRNA Uxs1 promoted CNV by sponging miR-335-5p, which stimulated PGF expression and subsequently activated the mTOR/p70 S6k pathway. Therefore, circRNA Uxs1 may serve as a promising therapeutic target for CNV. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Associations between exposure to brominated flame retardants and metabolic syndrome and its components in U.S. adults.
- Author
-
Che, Zhiqiang, Jia, Huixun, Chen, Renjie, Pan, Keyu, Fan, Zhe, Su, Chang, Wu, Zhenyu, and Zhang, Tao
- Published
- 2023
- Full Text
- View/download PDF
7. Sex as a predictor of response to cancer immunotherapy.
- Author
-
Zhang, Tao, Jia, Huixun, and Wu, Zhenyu
- Subjects
- *
IMMUNOTHERAPY , *TUMORS - Published
- 2018
- Full Text
- View/download PDF
8. Progression of Polypoidal Lesions Associated with Exudative Recurrence in Polypoidal Choroidal Vasculopathy.
- Author
-
Bo, Qiyu, Zhang, Min, Chen, Jieqiong, Jia, Huixun, Shen, Mengxi, Sun, Mengsha, Xu, Mengqiao, Feng, Jingyang, Yan, Quan, Yu, Yang, Huang, Peirong, Li, Tong, Wang, Fenghua, Rosenfeld, Philip J., and Sun, Xiaodong
- Subjects
- *
POLYPOIDAL choroidal vasculopathy , *ENDOTHELIAL growth factors , *LOGISTIC regression analysis , *VISUAL acuity , *REGRESSION analysis , *PHOTODYNAMIC therapy - Abstract
To investigate the characteristics of the branching vascular network (BVN) and polypoidal lesions in polypoidal choroidal vasculopathy (PCV) to determine near-term indicators that may predict exudative recurrence. Retrospective cohort study. Patients with PCV receiving anti–vascular endothelial growth factor (VEGF) monotherapy or anti-VEGF plus photodynamic therapy were followed for at least 1 year using swept-source OCT angiography (SS-OCTA) imaging. Patients were divided into 2 groups based on whether exudative recurrence occurred during follow-up. Multiple parameters were collected and compared between the 2 groups, such as age, gender, visual acuity, number of polypoidal lesions, lesion area at the first SS-OCTA visit, and total lesion area change from the first SS-OCTA visit to the last SS-OCTA visit. To evaluate the association between SS-OCTA imaging-based risk factors and the exudative recurrences, imaging features associated with PCV such as BVN growth and polypoidal lesion progression (enlargement, new appearance, and reappearance) at each follow-up visit were analyzed. The time intervals from the nonexudative visit with lesion progression to the corresponding exudative recurrence visit were documented to explore their association with exudative recurrences. Cox regression and logistic regression analyses were used. Association between BVN growth and polypoidal lesion progression with exudative recurrence. Thirty-one eyes of 31 patients (61% men) were included. Sixteen eyes had no recurrence of exudation, and 15 eyes had recurrence during follow-up. The average follow-up duration was 20.55 ± 6.86 months (range, 12–36 months). Overall, the recurrence group had worse best-corrected visual acuity (P = 0.019) and a greater increase in lesion area (P = 0.010). Logistical regression analysis showed that polypoidal lesion progression, including new appearance, enlargement, and reappearance of polypoidal lesions, was associated with exudative recurrences within 3 months (odds ratio, 26.67, 95% confidence interval, 3.77–188.54, P = 0.001). Growth of nonexudative BVN and progression of polypoidal lesions were found to be lesion characteristics associated with exudative recurrences, and progression of polypoidal lesions might serve as a stand-alone indicator for the near-term onset of exudation. In PCV, more frequent follow-up visits are recommended when polypoidal lesions show progression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 Trial.
- Author
-
Zhu, Hongcheng, Rivin del Campo, Eleonor, Ye, Jinjun, Simone II, Charles B., Zhu, Zhengfei, Zhao, Weixin, Amini, Arya, Zhou, Jialiang, Wu, Chaoyang, Tang, Huarong, Fan, Min, Li, Ling, Lin, Qin, Xia, Yi, Li, Yunhai, Li, Jiancheng, Mo, Miao, Jia, Huixun, Lu, Saiquan, and Wang, Juanqi
- Subjects
- *
SQUAMOUS cell carcinoma , *OVERALL survival , *SURVIVAL rate , *CHEMORADIOTHERAPY , *TREATMENT failure , *PILOT projects , *RESEARCH , *CONFIDENCE intervals , *CLINICAL trials , *TIME , *RESEARCH methodology , *METASTASIS , *LYMPH nodes , *CANCER relapse , *MEDICAL cooperation , *EVALUATION research , *FLUOROURACIL , *DRUG administration , *COMPARATIVE studies , *CISPLATIN , *RADIOTHERAPY , *PACLITAXEL , *ESOPHAGEAL tumors , *LONGITUDINAL method - Abstract
Purpose: To evaluate the feasibility and efficacy of involved-field irradiation in definitive chemoradiation therapy for locoregional esophageal squamous cell carcinoma.Methods and Materials: Patterns in recurrence and elective nodal failure were analyzed in patients from the previously published ESO-Shanghai 1 trial, who received definitive chemoradiation therapy with involved-field irradiation to 61.2 Gy in 34 fractions using intensity modulated radiation therapy planning. Nodal regions were delineated using the lymph node map from the sixth edition of the American Joint Committee on Cancer staging system. Elective nodal failure was defined as recurrence in the regional nodal area outside the planning target volume. Extensive elective nodal failure, defined as an extensive nodal area regardless of tumor location, was calculated for additional analysis. The incidental (ie, mean) irradiation dose of each node and each region was evaluated.Results: With a median follow-up of 48.7 months among survivors, the 3-year actuarial rate for overall survival was 53.6%, and the median overall survival was 44.8 months (95% confidence interval, 34.6-55.0). Of the 436 patients included in this study, 258 patients (59.2%) experienced treatment failure. Elective nodal failure was experienced by 37 patients (8.5%), 7 (1.6%) of whom encountered nodal-only failure. The 3-year actuarial rates of elective nodal control and elective nodal-only control were 89.7% and 97.9%, respectively. The median incidental dose of these nodes was 33.2 Gy (interquartile range [IQR], 1.3-50.7 Gy). The median distance of each node to the planning target volume was 1.4 cm (IQR, 0.6-4.9 cm). Extensive elective nodal failure was experienced by 51 patients (11.6%), and 20 (4.6%) patients had nodal-only failure. The 3-year extensive elective nodal control and extensive elective nodal control-only rates were 86.0% and 94.3%, respectively. The median incidental dose of these nodes was 23.2 Gy (IQR, 1.1-53.5 Gy). The median distance of each node to the planning target volume was 2.0 cm (IQR, 0.6-5.5 cm).Conclusion: Involved-field irradiation can achieve a low rate of isolated nodal failure and a satisfactory survival outcome. The use of elective nodal irradiation may be unnecessary in definitive chemoradiation therapy for the treatment of locoregional esophageal squamous cell carcinoma. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
10. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
- Author
-
Shi, Tingyan, Zhu, Jianqing, Feng, Yanling, Tu, Dongsheng, Zhang, Yuqin, Zhang, Ping, Jia, Huixun, Huang, Xiao, Cai, Yunlang, Yin, Sheng, Jiang, Rong, Tian, Wenjuan, Gao, Wen, Liu, Jihong, Yang, Huijuan, Cheng, Xi, and Zang, Rongyu
- Subjects
- *
CYTOREDUCTIVE surgery , *CA 125 test , *OVARIAN epithelial cancer , *OVARIAN cancer , *CANCER chemotherapy , *PROGRESSION-free survival , *GYNECOLOGIC oncology , *SURVIVAL analysis (Biometry) , *RESEARCH , *OVARIAN tumors , *CARBOPLATIN , *RESEARCH methodology , *ANTINEOPLASTIC agents , *CANCER relapse , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *PACLITAXEL , *STATISTICAL sampling - Abstract
Background: The benefits of secondary cytoreduction for platinum-sensitive relapsed ovarian cancer are still widely debated. We aimed to assess the efficacy of secondary cytoreduction plus chemotherapy versus chemotherapy alone in this patient population.Methods: This multicentre, open-label, randomised, controlled, phase 3 trial (SOC-1), was done in four primarily academic centres in China (two in Shanghai, one in Hangzhou, and one in Guangzhou). Eligible patients were women aged 18 years and older with platinum-sensitive relapsed epithelial ovarian cancer with a platinum-free interval of at least 6 months after the end of first-line platinum-based chemotherapy and were predicted to have potentially resectable disease according to the international model (iMODEL) score and PET-CT imaging. iMODEL score was calculated using six variables: International Federation of Gynecology and Obstetrics stage, residual disease after primary surgery, platinum-free interval, Eastern Cooperative Oncology Group performance status, serum level of cancer antigen 125 at recurrence, and presence of ascites at recurrence. An iMODEL score of 4·7 or lower predicted a potentially complete resection. As per a protocol amendment, patients with an iMODEL score of more than 4·7 could only be included if the serum level of cancer antigen 125 was more than 105 U/mL, but the principal investigators assessed the disease to be resectable by PET-CT. Eligible participants were randomly assigned (1:1) via a permuted block design (block size of six) and stratified by study centre, iMODEL score, residual disease at primary surgery, and enrolment in the Shanghai Gynecologic Oncology Group SUNNY trial, to undergo secondary cytoreductive surgery followed by intravenous chemotherapy (six 3-weekly cycles of intravenous paclitaxel [175 mg/m2] or docetaxel [75 mg/m2] combined with intravenous carboplatin [area under the curve of 5 mg/mL per min]; surgery group) or intravenous chemotherapy alone (no surgery group). Primary endpoints were progression-free survival and overall survival, analysed in all participants randomly assigned to treatment, regardless of treatment received (intention-to-treat [ITT] population). Here, we report the final analysis of progression-free survival and the prespecified interim analysis of overall survival. Safety was assessed in all participants who received their assigned treatment and had available adverse event data. This study is registered with ClinicalTrials.gov, NCT01611766, and is ongoing but closed to accrual.Findings: Between July 19, 2012, and June 3, 2019, 357 patients were recruited and randomly assigned to the surgery group (182) or the no surgery group (175; ITT population). Median follow-up was 36·0 months (IQR 18·1-58·3). In the no surgery group, 11 (6%) of 175 participants had secondary cytoreduction during second-line therapy while 48 (37%) of 130 participants who had disease progression crossed-over and had surgery at a subsequent recurrence. Median progression-free survival was 17·4 months (95% CI 15·0-19·8) in the surgery group and 11·9 months (10·0-13·8) in the no surgery group (hazard ratio [HR] 0·58; 95% CI 0·45-0·74; p<0·0001). At the interim overall survival analysis, median overall survival was 58·1 months (95% CI not estimable to not estimable) in the surgery group and 53·9 months (42·2-65·5) in the no surgery group (HR 0·82, 95% CI 0·57-1·19). In the safety population, nine (5%) of 172 patients in the surgery group had grade 3-4 surgical morbidity at 30 days, and no patients in either group had died at 60 days after receiving assigned treatment. The most common grade 3-4 adverse events during chemotherapy were neutropenia (29 [17%] of 166 patients in the surgery group vs 19 [12%] of 156 patients in the no surgery group), leucopenia (14 [8%] vs eight [5%]), and anaemia (ten [6%] vs nine [6%]). Four serious adverse events occurred, all in the surgery group. No treatment-related deaths occurred in either group.Interpretation: Secondary cytoreduction followed by chemotherapy was associated with significantly longer progression-free survival than was chemotherapy alone in patients with platinum-sensitive relapsed ovarian cancer, and patients should be counselled about the option of secondary cytoreduction in specialised centres. Long-term survival outcomes will be assessed using mature data on overall survival.Funding: Zhongshan Development Program.Translation: For the Chinese translation of the abstract see Supplementary Materials section. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.